Llwytho...
Autophagy Inhibition in BRAF-Driven Cancers
SIMPLE SUMMARY: BRAF is a protein kinase that is frequently mutationally activated in cancer. Mutant BRAF can be pharmacologically inhibited, which in combination with blockade of its direct effector, MEK1/2, is an FDA-approved therapeutic strategy for several BRAF-mutated cancer patients, such as m...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancers (Basel) |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8306561/ https://ncbi.nlm.nih.gov/pubmed/34298710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143498 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|